Abstract
Carboplatin-paclitaxel is standard of care for recurrent/advanced EC for which surgery ± radiation are not curative. Dostarlimab is an anti–programmed cell death 1 (PD-1) humanized monoclonal antibody that showed antitumor activity and an acceptable safety profile in patients (pts) with recurrent or advanced EC in the GARNET trial. Niraparib is a PARP inhibitor (PARPi) approved as 1L maintenance therapy in pts with advanced ovarian cancer following response to platinum-based chemo. Based on mechanism of action and preclinical findings, PARPi are being investigated for use in EC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have